Restricted accessResearch articleFirst published online 2014-11
Atomoxetine in Autism Spectrum Disorder: No Effects on Social Functioning;Some Beneficial Effects on Stereotyped Behaviors,Inappropriate Speech,and Fear of Change
The objective of this study was to investigate the short-term treatment effects of atomoxetine on autism spectrum disorder (ASD) symptoms in children and adolescents with both ASD and attention-deficit/hyperactivity disorder (ADHD).
Methods:
A total of 97 patients 6–17 years of age, with ASD and ADHD, were treated with 1.2 mg/kg/day of atomoxetine during an 8 week double-blind placebo-controlled period. Here, we investigated effects on two parent-based secondary outcome measures, the Aberrant Behavior Checklist (ABC) and the Children's Social Behavior Questionnaire (CSBQ).
Results:
After 8 weeks of double-blind treatment, atomoxetine administration was associated with significant treatment effects on the ABC subscales Hyperactivity, Inappropriate Speech, and Stereotypic Behavior, and on the CSBQ subscale Fear for Changes.
Conclusions:
Our study results indicate no beneficial effects of atomoxetine on social functioning. However, atomoxetine may ameliorate restricted and stereotyped behaviors and communication.
This study has been registered in ClinicalTrials.gov (www.clinicaltrials.gov) under registration number NCT00380692.
Get full access to this article
View all access options for this article.
References
1.
AdlerLA, LiebowitzM, KronenbergerW, QiaoM, RubinR, HollandbeckM, DeldarA, SchuhK, DurellT: Atomoxetine treatment in adults with attention deficit/hyperactivity disorder and comorbid social anxiety disorder. Depress Anxiety, 26:212–221, 2009.
2.
AmanMG, SinghNN, StewartAW, FieldCJ: The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects. Am J Ment Defic, 89:485–491, 1985.
3.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision. Washington, DC: American Psychiatric Association; 2000.
4.
AnagnostouE, HansenR: Medical treatment overview; traditional and novel psychopharmacological and complementary and alternative medications. Curr Opin Pediatr, 23:621–627, 2011.
5.
ArnoldLE, AmanMG, CookAM, WitwerAN, HallKL, ThompsonS, RamadanY: Atomoxetine for hyperactivity in autism spectrum disorders: Placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry, 45:1196–1205, 2006.
6.
DawsonG, BurnerK: Behavioral interventions in children and adolescents with autism spectrum disorder; a review of recent findings. Curr Opin Pediatr, 23:616–620, 2011.
7.
de BildtA, MulderEJ, HoekstraPJ, Lang vanND, MinderaaRB, HartmanCA: Validity of the Children's Social Behavior Questionnaire (CSBQ) in children with intellectual disability: Comprising the CSBQ with ADI-R, ADOS and clinical DSM-IV-TR Classification. J Autism Dev Disord, 39:1464–1470, 2009.
8.
FariesDE, YalcinI, HarderD, HeiligensteinJH: Validation of the ADHD Rating Scale as a clinician administered and scored instrument. J Attent Disord, 5:107–115, 2001.
9.
GellerD, DonnellyC, LopezF, RubinR, NewcornJ, SuttonV, BakkenR, PaczkowskiM, KelseyD, SumnerC: Atomoxetine treatment for pediatric patients with attention deficit/hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry, 46:1119–1127, 2007.
10.
HarfterkampMA, BuitelaarJK, MinderaaRB, Loo–Neus van deG, Gaag van derRJ, HoekstraPJ: Long term treatment with atomoxetine for ADHD symptoms in children with ASD: an open label extension study. J Child Adolesc Psychopharmacol, 23:1–6, 2013.
11.
HarfterkampM, van de Loo–NeusG, MinderaaRB, van der GaagRJ, EscobarR, SchachtA, PamulapatiS, BuitelaarJK, HoekstraPJ: A randomized double-blind study of atomoxetine versus placebo for ADHD symptoms in children with ASD. J Am Acad Child Adolesc Psychiatry, 51:733–741, 2012.
12.
HartmanCA, LuteijnE, SerraM, MinderaaRB: Refinement of the Childrens's Social Behavior Questionnaire (CSBQ): An instrument that describes the diverse problems seen in milder forms of PDD. J Autism Dev Disord, 36:325–342, 2006.
13.
HuffmanLC, SutcliffeTL, TannerISD, FeldmanHM: Management of symptoms in children with autism spectrum disorders; a comprehensive review of pharmacologic and complementary-alternative medicine treatments. J Dev Behav Pediatr, 32:56–68, 2011.
14.
JahromiLB, KasariCL, McCrackenJT, LeeLS, AmanMG, McDougleCJ, ScahillL, TierneyE, ArnoldLE, VitielloB, RitzL, WitwerA, KustanE, GhumanJ, PoseyDJ: Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity. J Autism Dev Disord, 39:395–404, 2009.
15.
JouRJ, HandenBL, HardanAY: Retrospective assessment of atomoxetine in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol, 15:325–330, 2005.
16.
KarabekirogluK, AmanMG: Validity of the aberrant behavior checklist in a clinical sample of toddlers. Child Psychiatry Hum Dev, 40:99–110, 2009.
17.
KingBH, HollanderE, SikichL, McCrackenJT, ScahillL, BregmanJD, DonnellyCL, AnagnostouE, DukesK, SullivanL, HirtzD, WagnerA, RitzL, STAART Psychopharmacology Network: Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: Citalopram ineffective in children with autism. Arch Gen Psychiatry, 66:583–590, 2009.
18.
LeyferOT, FolsteinSE, BacalmanS, DavisNO, DinhE, MorganJ, Tager–FlusbergH, LainhartJE: Comorbid psychiatric disorders in children with autism: Interview development and rates of disorders. J Autism Dev Disord, 36:849–861, 2006.
19.
LuteijnE, LuteijnF, JacksonS, VolkmarF, MinderaaRB: The Children's Social Behavior Questionnaire for milder variants of PDD problems: Evaluation of the psychometric characteristics. J Autism Dev Disord, 30:317–330, 2000.
20.
MarcusRN, OwenR, KamenL, ManosG, McQuadeRD, CarsonWH, AmanMG: A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry, 48:1110–1119, 2009.
21.
MarcusRN, OwenR, ManosG, MankoskiR, KamenL, McQuadeRD, CarsonWH, Corey–LislePK, AmanMG: Aripiprazole in the treatment of irritability in pediatric patients (aged 6–17 years) with autistic disorder: Results from a 52-week, open label study. J Child Adolesc Psychopharmacol, 21:229–236, 2011.
22.
McDougleCJ, ScahillL, AmanMG, McCrackenJT, TierneyE, DaviesM, ArnoldLE, PoseyDJ, MartinA, GhumanJK, ShahB, ChuangSZ, SwiezyNB, GonzalezNM, HollwayJ, KoenigK, McGoughJJ, RitzL, VitielloB: Risperidone for the core symptom domains of autism: Results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry, 162:1142–1148, 2005.
RutterM, Le CouteurA, LordC: Autism Diagnostic Interview Revised Manual. Los Angeles: Western Psychological Services; 2003.
25.
TroostPW, SteenhuisMP, Tuynman-QuaHG, KalverdijkLJ, BuitelaarJK, MinderaaRB, HoekstraPJ: Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study. J Child Adolesc Psychopharmacol, 16:611–619, 2006.
